Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Sherry A Bradford

Sherry A Bradford

AccuTheranostics, Inc., USA

Title: Dichloroacetate (DCA) as an oncology chemotherapeutic agent? What’s all the hype and is it warranted? Complete with clinical outcomes

Biography

Biography: Sherry A Bradford

Abstract

Chemotherapeutic treatment regimens tend to be deleterious and toxic to cancer patients. Thus, today many clinicians are changing their clinical practices opting for targeted and/or ancillary drug treatments that kill the tumor cell populations while sparing healthy cells. Greater than 70% of all cancer types rely on cytosolic aerobic glycolysis for energy production, an inefficient means of generating ATP rather than mitochondrial oxidative phosphorylation resulting in an acidic microenvironment conducive to their growth and proliferation. DCA inhibits Pyruvate Dehydrogenase Kinase (PDK) thereby increasing influx of pyruvate into the mitochondria, promoting glucose oxidation, reversing the suppressed mitochondria thus promoting apoptosis in cancer cells. Thus, it would be reasonable to propose that cancer cells would likely be sensitive DCA. Therefore, a prospective study of the efficacy of DCA as a potential chemotherapeutic agent was conducted.